Clinuvel Pharmaceuticals vs Xilio Therapeutics
Clinuvel Pharmaceuticals is the larger business, with $64.3m of revenue in fiscal 2026 against $43.8m for Xilio Therapeutics (1.5 times as much). Xilio Therapeutics grew faster (589.9% against 5.2%). Clinuvel Pharmaceuticals kept more of each dollar of sales as profit: a net margin of 36.0% against -80.1%. Clinuvel Pharmaceuticals carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | Clinuvel PharmaceuticalsCUVL, 2026 | Xilio TherapeuticsXLO, 2025 |
|---|---|---|
| Revenue | $64.3m | $43.8m |
| Revenue growth | 5.2% | 589.9% |
| Net income | $23.2m | −$35.0m |
| Operating margin | 43.4% | -95.9% |
| Net margin | 36.0% | -80.1% |
| Return on equity | 13.4% | -132.5% |
| Free cash flow | $11.8m | −$5.5m |
| Cash | $13.9m | $138m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 76 |
| Market value | $256m | $56.6m |
| Price vs our value range | — | — |
| Moat score | — | — |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 2 sales |